			. TO ON DI TI	 2-99-
to this collection of infor	DOCUMENTATION mation is estimated to average 1 hour per re-	sponse, including the time for the sponse, including the burden estimat	AFRL-SR-BL-TI	Taintaining
the data needed, and completing and	a companie for Information Oper	SHOUR SUD MEDOURS IN THE SOURCE	000	
reducing this burden to washington head and Budget. Paperwork Reduction	Project (0704-0188), Washington, DC 2050: 2. REPORT DATE	2 DE SORT SV	,	FINAL
1. AGENCY USE ONLY (Leave	2. REPORT BATE	2/15/96	$\frac{3-3/31/99}{5. \text{ FUNDING}}$	· · · · · · · · · · · · · · · · · · ·
4. TITLE AND SUBTITLE			5, FUNDING	NUMBERS
Biomarkers of To:	xicant Exposure		F49620	)-96-1-0074
6. AUTHOR(S)				
Dr. Frank Siegel				
Dr. Steven Korng	uth			
			8. PERFORM	ING ORGANIZATION
7. PERFORMING ORGANIZATION	I NAME(S) AND ADDRESS(ES)	o.f	REPORT	NUMBER
Board of Regents	of the Universit	у от		
Wisconsin Syst	ems			
750 University A	venue	•		
Madison, WI 5370	16-1490			
			40 CDONS	DRING / MONITORING
9. SPONSORING / MONITORING	AGENCY NAME(S) AND ADDR	ESS(ES)	AGENC	Y REPORT NUMBER
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
AFOSR/NL 801 N. Randolph	St Room 732			
Arlington, VA 22	2203-1977			
Arlington, VA 22	7200 2011			
1				
THE STATE OF THE S			-	
11. SUPPLEMENTARY NOTES				
	. 100	100007	AA/ 1	12b. DISTRIBUTION CODE
12a. DISTRIBUTIONS	TATEMENTA   Y	44114117	11114	
Approved for Pu	Mill Heleaser	,, ,, ,,	VVT	
Distribution	Unlimited			
13. ABSTRACT (Maximum 200	words)	•	in rodent me	odels with a focus on lead
The goal of this study	was to develop biomarker	s of toxicant expo	osure, in rodent in	odels, with a focus on lead significant alterations in
a and the military jet fi	el JP8. Our results demo	nstrated that these	e toxicants caused	significant alterations in of the family of glutathione
the levels of specific do	Stoxication enzymes. The	many environme	ntal toxicants and	drugs. Studies on lead
S-transferases (GSTs),	enzymes which detoxify	many chrinomic	urred at lead level	s seen in the environment and function in lead-treated
effects on kidney found	d that large increases in u	nese enzymes occ	lidnov structure	and function in lead-treated
rate suggested that chi	anges in GSTs are a sensi	tive tissue marker	of toxicant expos	sure. Studies on
lats, suggested that the	anges in GS is are a sensi	anges in GSTs ref	flected changes in	gene expression, and
mechanisms demotism	deams, did not result from	m oxidative stress	s. Inhalation expos	sure of JP8 was shown to
affect other members	of the GS1 family in the	ilei vous system, v	te of IP8 toxicity	this is of Air Force
significance, since vis	ual and motor functions a	are controlled by I	renna and cereben	uiii.
3.6				

-				1	5. NUMBER OF PAGES
	14. SUBJECT TERMS			1	6. PRICE CODE
	17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	2	0. LIMITATION OF ABSTRACT
				Stand	lard Form 298 (Rev. 2-89)

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

# FINAL TECHNICAL REPORT AIR FORCE OFFICE OF SCIENTIFIC RESEARCH GRANT NO. F49620-96-1-0074 BIOMARKERS OF TOXICANT EXPOSURE

PRINCIPAL INVESTIGATOR: FRANK L. SIEGEL, Ph.D. CO-PRINCIPAL INVESTIGATOR: STEVEN E. KORNGUTH, Ph.D. UNIVERSITY OF WISCONSIN-MADISON

MAY 1, 1999

1. OBJECTIVES: To characterize biomarkers of exposure to toxic levels of lead and also to the jet fuel JP8.

#### 2. RESEARCH RESULTS

- a) Background This project was designed to develop exposure biomarkers for lead and JP8 toxicity. In research supported by our original AFOSR grant, we found that high dose lead administration caused dramatic increases in specific isoenzyme forms of the detoxication enzyme glutathione S-transferase (GST) in kidney. Increases in these GSTs were followed by pathobiological changes in renal architecture and decreased kidney function, suggesting that increases in kidney GSTs were an early warning sign of lead toxicity and were valid tissue biomarkers. These studies were made possible by our development of an analytical protocol which allowed for the quantitative analysis of fifteen GST isoenzymes, using high performance liquid chromatography (hplc). Our goals for the period covered by this report included the following:
- (1) To determine the effects of lead exposure on the expression of GSTs in tissues other than kidney.
- (2) To determine if the lead-related increases in GSTs were the result of increased transcription (gene expression).
- (3) To determine if lead at low doses which mimic environmental exposure also cause changes in tissue GSTs.
- (4) To test the prevailing hypothesis that lead effects on GST expression result from oxidative stress.
- (5) To determine if inhalation exposure to the aviation jet fuel JP8 also causes changes in tissue GSTs.

Each of these goals has been attained and the results have either been published or, in the case of goal (5), submitted for publication.

## b) Inorganic Lead Study

**Experimental design** - Adult Sprague-Dawley rats were given daily intraperitoneal (i. p.) injections of lead acetate; control rats were given equal volume injections of physiological saline.

#### Results

**Dose-response study** - A dose-response study of the effect of lead acetate administration on rat kidney glutathione S-transferase was performed, and the results demonstrate that increases

in GST activity are highly correlated to the lead dose and the concomitant blood lead levels. Sprague-Dawley rats were injected with doses of lead acetate ranging from 0.1 to 114 mg/kg (0.3 to 300 µmole/kg) for 3 consecutive days and sacrificed 24 hr later. Kidney GST activity, GST isoform HPLC profiles, blood lead analysis, serum clinical chemistry panels, and light microscopy were performed. Treatment with 1 mg/kg lead acetate corresponded to a blood lead level of 26  $\mu$ g/dl and produced a significant increase in total GST activity which continued to increase with dose up to 38 mg/kg. This increase in GST activity paralleled the changes in blood lead levels. When the data sets of dose, weight loss, blood lead levels, and total GST activity were correlated with respect to each other. Individual GST isoforms exhibited different thresholds and maxima. rGSTP1 and rGSTM1 had thresholds of 1 mg/kg and 3.8 mg/kg respectively, very similar rates of increase with dose, and a maximum yield that was 450% above control at a dose of 38 mg/kg for both enzymes. rGSTA1 and rGSTA3 showed similar thresholds (1 mg/kg) and maximal fold increase (275%) but varied in the relative response to each dose. rGSTA2 and rGSTM2 had only modest increases beginning at a dose of 38 mg/kg. Minimal changes in rGSTA4, M3, and M6 and microscopic structural changes were detected only at the highest dose. A standard clinical chemistry panel was run on serum from each animal, and no significant changes were observed for any component, including, blood urea nitrogen (BUN), creatinine, glucose and γ-glutamyl transferase (GGT). These results indicate that renal GST increases occur at lead levels which are environmentally significant, and at doses that precede any clinical serum or histological changes, and also suggest that GST can serve as highly sensitive biomarker of lead exposure.

Lead mode of action study - The effect of acute exposure to lead acetate on the expression of glutathione S-transferase isoenzymes, level of glutathione, and amount of malonaldehyde in rat kidney and liver was determined. The purpose of this study was to determine if GSH depletion and oxidative stress are responsible for the increase in GST following lead exposure. In kidney rGSTM1, rGSTA2, and rGSTP1 all increase following i.p. injection of lead. The level of GSH is not effected 0.5 or 1 hour after lead exposure, but is increased 3, 6, 12, and 24 hours after a single injection of lead. MDA levels (a marker of lipid peroxidation) do not change in kidney. Therefore, we conclude that the increases in GST isoenzymes that occur in kidney following lead exposure are not dependent upon GSH depletion or oxidative stress. In liver, GSH depletion (61% of control 12 hours after lead treatment) and increased MDA production (2.5-fold increase 6 hours after lead exposure) occur, while rGSTM1 and rGSTA2 do not increase. Immunoperoxidase light microscopy and immunogold electron microscopy reveal that the increase in kidney GSTM1 and GSTP1 occurs in both the nuclei, cytoplasm, and microvilli of proximal tubules. Northern blot analysis of rGSTA2 and rGSTP1 showed that the mRNA increase of these two GSTs following lead exposure can be inhibited by actinomycin D, suggestion transcriptional induction. 2-Dimensional gel electrophoresis show not only induction of rGSTP1 in kidney after lead treatment, but also appearance of newly charged species of this isoenzyme. This study demonstrates that acute lead exposure causes dramatic changes in the subcellular distribution and expression of GST isoenzymes, and that these changes are not a result of GSH depletion or oxidative stress.

## c. Organic lead study

**Experimental design -** Adult male Sprague-Dawley rats were given injections of triethyl lead chloride; control animals received injections of physiological saline.

Results - The effects of triethyl lead chloride (TEL) on the expression of glutathione Stransferases (GSTs) and NAD(P)H:quinone oxidoreductase (QR) in rat liver and kidney were determined. Fischer 344 rats were given one injection intraperitoneally of TEL. GST activity, GST isoform levels, mRNA levels of alpha class GST isoforms A1, A2, and A3 and activity of QR were determined. Treatment of rats with TEL caused a significant increase in GST activity in kidney. The levels of GSTs M1, P1, A3, A1, A2, and A4 were significantly elevated in kidney, while the level of GSTM2 was unchanged. The largest increase was a 3.2fold increase in GSTM1. The levels of GSTA1, A2, and A3 mRNA in kidney also increased significantly after injection of TEL. In liver, TEL injection resulted in decreased GST activity; the level of hepatic GSTs M2, P1, M3, A1, A2, and A4 decreased significantly following the injection of TEL. The largest decrease was a 40 percent reduction of GST A1 In contrast, the level of liver GST A3 increased from day 4 through day 14 after injection of TEL. The levels of liver mRNAs coding for alpha class GSTs YA1, A2, and A3 were reduced 12 hours after injection of TEL. By 24 hours after TEL injection, GST A1 and A2 mRNA levels returned to basal level while A3 message increased to a level higher than controls. The activity of QR was elevated 1.5-fold in kidney and 2.7-fold in liver 14 days after the injection of TEL. This report demonstrates that administration of organic lead significantly affects GST expression and QR activity in a tissue-specific and isoform-specific manner. An unexpected observation was the onset of violent aggressive behavior in rats given triethyl lead. These results indicate that the effects of TEL on GST expression and QR activity must involve more than a single promoter.

c) JP8 Jet Fuel Study - Swiss-Webster mice and adult rats were exposed to JP8 aerosol in the AFOSR-supported Inhalation Toxicology Laboratory of Dr. Mark Witten, Departement of Pediatrics, University of Arizona Medical School.

**Experimental design** - In the inhalation toxicology study, animals were exposed to JP8 aerosol in the AFOSR-supported laboratory of Dr. Mark Witten, Department of Pediatrics, University of Arizona and tissue samples were analyzed in our facilities at the University of Wisconsin.

Results - Male mice were exposed to aerosolized jet fuel (JP8+100) at concentrations of 1000 mg/m³ or 2500 mg/m³, 1-10micron diameter particle size. Exposure was for one hour per day for seven days. The animals were then sacrificed and we examined the retina, brain regions, liver, lung and kidney to determine whether such treatment resulted in changes in the concentration or cell distribution of the enzyme glutathione S transferase (GST). The retina and cerebellum tissues were of particular interest because of the critical roles of proprioception and vision in Air Force personnel. and then sacrificed. The retina was studied

immunohistochemically while other brain regions, including cerebellum were studied immunohistochemically, by HPLC, and by GST enzyme activity. Other tissues were studied by HPLC. The immunohistochemical studies revealed that the JP8+100 affected the concentration of GSTs in the radial glial cells of cerebellum and retina as determined immunohistochemically. The major changes observed were the increased immunoreactivity of the anti-GSTM1 antisera with the Bergmann glial cells of cerebellum and Muller cells of retina. We also observed a decreased immunoreactivity of the cerebellar molecular layer with anti-GSTP. These results are consistent with the functional changes in proprioception and light sensitivity observed in personnel who are exposed to high concentrations of JP8+100.

#### 3. PERSONNEL SUPPORTED

Frank L. Siegel, Ph.D., Principal Investigator

Steven E. Kornguth, Ph.D., Co-Principal Investigator

Lynda S. Wright, M.S., Med. Tech., Senior Researcher

Shelli A. Nelson, B.S., Research Specialist

Danniel A. Daggett Ph. D. (1997), Graduate Research Assistant (no salary from AFOSR)

## 4. PUBLICATIONS (1996-1999)

## a) Published or In Press

McGuire, S., Daggett, D., Bostad, E., Schroeder, S., Siegel, F. And Kornguth, S. (1996) Cellular Localization of Glutathione S-Transferases in Retinas of Control and Lead-Treated Rats, Investigative Ophthalmology and Visual Science 37, 833-842.

Daggett, D. A., Nuwaysir, E. F., Nelson, S. A., Wright, L. S., Kornguth, S. E. And Siegel, F. L. (1996) Effects of triethyl lead administration on the expression of glutathione S-transferase isoenzymes and quinone reductase in rat kidney and liver. Toxicology 117, 61-71.

McGuire, S., Daggett, D., Bostad, E., Schroeder, S., Wright, L., Siegel, F. and Kornguth, S. (1997), Increased levels of glutathione transferases and appearance of novel alpha class isoenzymes in kidneys of mice exposed to mercuric chloride. Nephron 77, 452-460.

Witzmann, F.A., Daggett, D.A., Fultz, C.D., Nelson, S.A., Wright, L.S., Kornguth, S.E. and Siegel, F. L. (1998) Glutathione S-transferases: Two-dimensional electrophoretic protein markers of lead exposure. Electrophoresis 19, 1322-1335.

Witzmann, F. A., Fultz, C. D., Grant, R. A., Wright, L. S., Kornguth, S. E. and Siegel, F. L. (1998) Differential expression of cytosolic proteins in the rat kidney and cortex: preliminary proteomics. Electrophoresis 19, 2491-2497.

Daggett, D. A., Oberley, T. D., Nelson, S. A., Wright, L. S., Kornguth, S. E. and Siegel, F. L. (1998) Effects of lead on rat kidney and liver: GST expression and oxidative stress. Toxicology 128, 191-206.

Wright, L. S., Kornguth, S. E., Oberley, T. D. and Siegel, F. L. (1998) Effects of lead on glutathione S-transferase expression in rat kidney: a dose-response study. Toxicol. Sci. 46, 254-259.

Witzmann, F. A., Fultz, C. D., Grant, R. A., Wright, L. S., Kornguth, S. E. and Siegel, F. L. (1999) Regional protein alterations in rat kidneys induced by lead exposure. Electrophoresis 20, 943-951.

## b) Submitted for Publication

Wright, L. S., McGuire, S., Bostad, E., Nelson, S. A., Daggett, D. A., Witten, M. L., Siegel, F. L. and Kornguth, S. E., Effects of jet fuel JP8+100 aerosol on glutathione S-transferase expression in retina and cerebellum of Swiss-Webster mice.

### 5. DISSERTATIONS

Daggett, D. A. (1997) Effects of Lead on the Expression of Glutathione S-Transferases, Ph.D. Dissertation, University of Wisconsin - Madison. Obtainable through the University of Wisconsin - Madison Memorial Library. All key results included in this dissertation have been published.

#### 6. INTERACTIONS/TRANSITIONS

#### a) Invited presentations

Frank L. Siegel: Merck Lectureship, Memorial University, St. John's Newfoundland, May, 1997.

Steven E. Kornguth: Lectures to Institute for Advanced Technology, University of Texas at Austin, February, 1999.

Steven E. Kornguth: DARPA, Monterey, California, 1998.

Steven E. Kornguth: AFOSR JP8 Toxicology Conference, San Antonio, Texas, April, 1998

Steven E. Kornguth and Lynda S. Wright: AFOSR JP-8 Jet Fuel Toxicology Workshop, The University of Arizona, December, 1998.

# b) Consulting for the Department of Defense

Steven E. Kornguth: Environmental Sciences Group, Brooks Air Force Base, San Antonio, Texas; Institute for Defense Analysis, Alexandria, Virginia.

## **APPENDIX**

In a preliminary experiment to determine the neurochemical effects of JP8 exposure, adult rats were exposed to JP8 aerosol at a dose of 1000 mg/m³ for either 7 or 14 days in the laboratory of Dr. Mark Witten, University of Arizona. We analyzed brain regions for catecholamines and serotonin neurotransmitters and their metabolites.

# Neurotransmitter Levels after 7 and 14 day JP8 Aerosol Exposure

Neurotransmitter	striatum control	7 day striatum	14 day striatum
Norepinephrine	$3.867 \pm 0.677$	$2.002 \pm 0.373$	$3.352 \pm 0.34$
Dopamine	$5.046 \pm 0.498$	$6.846 \pm 0.816$ *	$2.365 \pm 1.885$
DOPAC	$23.47 \pm 2.12$	$45.93 \pm 6.22**$	$20.00 \pm 2.74$
HVA	$1.922 \pm 0.172$	$2.982 \pm 0.539*$	$1.246 \pm 0.191$ *
Serotonin	$7.981 \pm 0.931$	$4.949 \pm 0.741$ *	$5.607 \pm 0.341$ *
5-HIAA	$3.807 \pm 0172$	$5.041 \pm 0.803$	$2.441 \pm 0.172$
Neurotransmitter	cortex control	7 day cortex	14 day cortex
Norepinephrine	$2.178 \pm 0.223$	$1.270 \pm 0.129*$	$1.742 \pm 0.168$
Dopamine	$0.802 \pm 0.108$	$0.380 \pm 0.050$ *	$0.385 \pm 0.310$ *
DOPAC	$0.827 \pm 0.188$	$0.525 \pm 0.060$	$1.722 \pm 0.258*$
HVA	$0.069 \pm 0.010$	$0.038 \pm 0.003$	$0.094 \pm 0.011$
Serotonin	$4.357 \pm 0.290$	$2.243 \pm 0.394*$	$4.036 \pm 0.594$
5-HIAA	$2.775 \pm 0.406$	$1.964 \pm 0.290$	$2.528 \pm 0.284$
*			•
		<b>7</b> 1 11 11 11 11 11 11 11 11 11 11 11 11	1.4 days assah allum
Neurotransmitter	cerebellum control	7 day cerebellum	14 day cerebellum
Norepinephrine	$2.251 \pm 0.281$	$1.674 \pm 0.162$	$1.731 \pm 0.179$
Norepinephrine Dopamine	$2.251 \pm 0.281$ $0.823 \pm 0.062$	$1.674 \pm 0.162$ $0.619 \pm 0.116$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$
Norepinephrine Dopamine DOPAC	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$
Norepinephrine Dopamine DOPAC HVA	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$
Norepinephrine Dopamine DOPAC HVA Serotonin	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$
Norepinephrine Dopamine DOPAC HVA	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$
Norepinephrine Dopamine DOPAC HVA Serotonin	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter Norepinephrine	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$ hippocamp control	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$ 7 day hippocamp	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$ 14 day hippocamp
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$ <b>hippocamp control</b> $2.112 \pm 0.321$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$ <b>7 day hippocamp</b> $2.929 \pm 0.504$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$ 14 day hippocamp $2.657 \pm 0.343$
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter Norepinephrine Dopamine	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$ <b>hippocamp control</b> $2.112 \pm 0.321$ $0.860 \pm 0.210$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$ 7 day hippocamp $2.929 \pm 0.504$ $0.660 \pm 0.103$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$ 14 day hippocamp $2.657 \pm 0.343$ $0.658 \pm 0.143$
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter Norepinephrine Dopamine DOPAC	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$ <b>hippocamp control</b> $2.112 \pm 0.321$ $0.860 \pm 0.210$ $2.246 \pm 0.818$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$ <b>7 day hippocamp</b> $2.929 \pm 0.504$ $0.660 \pm 0.103$ $2.162 \pm 0.455$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$ 14 day hippocamp $2.657 \pm 0.343$ $0.658 \pm 0.143$ $3.038 \pm 0.952$
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA  Neurotransmitter Norepinephrine Dopamine DOPAC HVA	$2.251 \pm 0.281$ $0.823 \pm 0.062$ $0.330 \pm 0.379$ $0.068 \pm 0.006$ $1.085 \pm 0.146$ $0.766 \pm 0.052$ <b>hippocamp control</b> $2.112 \pm 0.321$ $0.860 \pm 0.210$ $2.246 \pm 0.818$ $0.158 \pm 0.039$	$1.674 \pm 0.162$ $0.619 \pm 0.116$ $0.341 \pm 0.045$ $0.065 \pm 0.007$ $0.741 \pm 0.102$ $0.662 \pm 0.106$ 7 day hippocamp $2.929 \pm 0.504$ $0.660 \pm 0.103$ $2.162 \pm 0.455$ $0.133 \pm 0.023$	$1.731 \pm 0.179$ $0.423 \pm 0.052*$ $0.335 \pm 0.056$ $0.060 \pm 0.008$ $0.839 \pm 0.120$ $0.703 \pm 0.128$ 14 day hippocamp $2.657 \pm 0.343$ $0.658 \pm 0.143$ $3.038 \pm 0.952$ $0.209 \pm 0.026$

Neurotransmitter Norepinephrine Dopamine DOPAC HVA Serotonin	midbrain control $4.284 \pm 0.393$ $0.780 \pm 0.100$ $2.579 \pm 0.448$ $0.246 \pm 0.062$ $7.396 \pm 0.209$	7 day midbrain $3.729 \pm 0.309$ $0.405 \pm 0.045$ $2.623 \pm 0.303$ $0.133 \pm 0.020$ $6.490 \pm 0.370$	14 day midbrain $3.412 \pm 0.370$ $0.426 \pm 0.072$ $2.153 \pm 0.303$ $0.164 \pm 0.033$ $5.780 \pm 0.392*$
5-HIAA	$4.626 \pm 0.305$	$4.389 \pm 0.334$	$3.841 \pm 0.426$
Neurotransmitter	brain stem control	7 day brain stem	14 day brain stem
Norepinephrine Dopamine DOPAC HVA Serotonin 5-HIAA	·	$3.057 \pm 0.428$ $0.129 \pm 0.013$ $0.732 \pm 0.112$ $0.089 \pm 0.011$ $4.421 \pm 0.634$ $2.610 \pm 0.333$	$2.600 \pm 0.231$ $0.198 \pm 0.032$ $0.584 \pm 0.131$ $0.114 \pm 0.013$ $4.709 \pm 0.545$ $2.707 \pm 0.289$

These preliminary results indicate that JP8 inhalation produces significant changes in the levels of brain neurotransmitters.

<sup>\*-</sup> p< 0.05 \*\*- p<0.01